| Website | versantventures.com |
| Phone | (650) 233-7877 |
| Employees | 12 |
| Founded | 1999 |
| Description | Venture capital Firm |
| Versant Ventures, 8/08 | $500M |
Versant Ventures is a leading healthcare-focused venture capital firm specializing in early-stage investments in medical devices, biotechnology and pharmaceuticals, healthcare services, and healthcare information technology. The firm, founded in 1999, consists of a seasoned team of twelve managing directors with more than 130 years of venture capital investing experience and more than 150 years of operating experience.
| Company | Date | Round | Size | Participants |
| GenSight Biologics | 4/13 | Series A | €32M | 4 |
| Theraclone Sciences | 3/13 | Series B | $8M | 8 |
| Novira Therapeutics | 3/13 | Series A | $7.5M | 1 |
| Holaira | 2/13 | Series C | $10M | 4 |
| Glaukos | 2/13 | Series F | $30M | 7 |
| Ocular Therapeutix | 1/13 | Series D | $23.8M | 4 |
| Ceterix Orthopaedics | 1/13 | Series B | $19.5M | 3 |
| Flexion Therapeutics | 12/12 | Series B | $20M | 5 |
| CardiAQ Valve Technologies | 11/12 | Series B | $37.3M | 2 |
| Cerephex | 10/12 | Series A | 3 | |
| Innovative Pulmonary Solutions | 9/12 | Venture Round | $10.6M | 4 |
| ROX Medical | 9/12 | Venture Round | $6M | 2 |
| Alter-G | 8/12 | Series C | $10M | 1 |
| Benvenue Medical | 6/12 | Series D | $25M | 4 |
| Zyga Technology | 5/12 | Series C | $25M | 4 |
| OpGen | 3/12 | Venture Round | $17M | 6 |
| Sequent Medical | 3/12 | Series C | $26M | 4 |
| Groove Biopharma | 12/11 | Series B | $6M | 4 |
| Advanced ICU Care | 11/11 | Series D | $8M | 4 |
| AcuFocus | 11/11 | Series F | $65M | 5 |
| Kythera Biopharmaceuticals | 9/11 | Series D | $37.4M | 7 |
| Intuity Medical | 8/11 | Series D | $12M | 5 |
| WaveTec Vision | 5/11 | Series D | $15.9M | 4 |
| Benvenue Medical | 4/11 | Series C | $35.5M | 3 |
| Augmenix | 1/11 | Debt | $3M | 3 |
| Synosia Therapeutics | 10/10 | Series C | $30M | 7 |
| OpGen | 9/10 | Series B | $17M | 5 |
| Okairos | 9/10 | Series B | $20.5M | 2 |
| Immune Design | 7/10 | Series B | $32M | 4 |
| Veracyte | 6/10 | Series B | $28M | 4 |
| Sequent Medical | 5/10 | Series B | $15.6M | 3 |
| Mirina | 4/10 | Series A | $3.9M | 5 |
| Intuity Medical | 1/10 | Series D | $64M | 6 |
| Fluidigm | 11/09 | Venture Round | $7.5M | 8 |
| Metabolex | 11/09 | Venture Round | $8.6M | 12 |
| Augmenix | 10/09 | Series B | $6.1M | 4 |
| Flexion Therapeutics | 10/09 | Series A | $33M | 3 |
| Ocular Therapeutix | 6/09 | Series C | $15M | 3 |
| Transcend Medical | 6/09 | Series A | $9.4M | 3 |
| Anaphore | 6/09 | Series A | $13M | 5 |
| Clovis Oncology | 5/09 | Series A | $145M | 7 |
| Ambrx | 4/09 | Series D | $10M | 7 |
| RedBrick Health | 4/09 | Series C | $15M | 4 |
| LensX Lasers | 3/09 | Series B | $22.4M | 3 |
| Rennovia | 3/09 | Series A | $12.3M | 2 |
| Alter-G | 1/09 | Series B | $8M | 1 |
| Synosia Therapeutics | 1/09 | Series B | $29M | 7 |
| Cardiac Concepts | 10/08 | Series B | $21M | 6 |
| APT Pharmaceuticals | 9/08 | Series A | $32M | 7 |
| Microfabrica | 9/08 | Series B | $22.5M | 6 |
| Glaukos | 8/08 | Series D | $35M | 7 |
| Immune Design | 7/08 | Series A | $18M | 3 |
| Vaccsys | 6/08 | Venture Round | $9M | 3 |
| Kythera Biopharmaceuticals | 5/08 | Series C | $30M | 9 |
| NovaSys | 5/08 | Venture Round | $49.5M | 10 |
| Anaphore | 4/08 | Venture Round | $8M | 2 |
| Cameron Health | 3/08 | Series E | $14M | 4 |
| PhaseRx | 2/08 | Series A | $19M | 3 |
| Benvenue Medical | 1/08 | Series B | $15M | 3 |
| OpGen | 9/07 | Series A | $23.6M | 4 |
| Metabolex | 4/07 | Series D | $32M | 16 |
| Fluidigm | 1/07 | Series E | $17M | 10 |
| Synosia Therapeutics | 1/07 | Venture Round | $32.5M | 4 |
| NeoVista | 12/06 | Series C | $41M | 6 |
| Impedance Cardiology Systems | 11/06 | Series B | $5M | 2 |
| Neurotech | 11/06 | Series B | $35M | 12 |
| Achaogen | 10/06 | Series B | $26M | 5 |
| NeoVista | 9/06 | Series B | $26M | 4 |
| Kythera Biopharmaceuticals | 7/06 | Series B | $30M | 6 |
| Pathwork Diagnostics | 7/06 | Venture Round | $11M | 5 |
| MedManage Systems | 4/06 | Series D | $10.8M | 4 |
| Kythera Biopharmaceuticals | 9/05 | Venture Round | $1M | 1 |
| Oxonica | 7/05 | Venture Round | $2.5M | 1 |
| Five Prime Therapeutics | 2/05 | Venture Round | $45M | 10 |
| Glaukos | 9/02 | Series A | $10M | 3 |
